Twist Bioscience (TWST) EBIT (2017 - 2026)

Twist Bioscience (TWST) has reported EBIT for 10 consecutive years, with -$36.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBIT fell 20.45% year-over-year to -$36.3 million in Q2 2026; TTM through Jun 2026 was -$145.0 million, a 1.83% decrease from a year earlier, with the FY2025 full-year figure at -$136.3 million, up 38.3% from the prior year.
• EBIT was -$36.3 million for Q2 2026 at Twist Bioscience, up from -$45.9 million in the prior quarter.
• Over five years, EBIT peaked at -$29.9 million in Q3 2025 and troughed at -$88.9 million in Q2 2024.
• A 5-year average of -$48.2 million and a median of -$46.4 million in 2023 frame the typical range for EBIT.
• Across the five-year window, EBIT slumped 59.99% in 2022 and soared 66.13% in 2025, its largest moves.
• Over 5 years, EBIT stood at -$44.6 million in 2022, then slipped by 5.26% to -$47.0 million in 2023, then climbed by 26.25% to -$34.6 million in 2024, then rose by 5.03% to -$32.9 million in 2025, then dropped by 10.27% to -$36.3 million in 2026.
• The last three EBIT figures came in at -$36.3 million (Q2 2026), -$45.9 million (Q1 2026), and -$32.9 million (Q4 2025), per Business Quant data.